Observe Medical (OBSRV) Company Presentation summary

Strategic vision and business model

• Focus on building a scalable Nordic medtech platform, integrating proprietary product development, commercialization, and manufacturing to drive profitable growth.

• Platform supports innovative start-ups lacking commercial, regulatory, and manufacturing capabilities, with M&A opportunities to optimize the ecosystem.

• Emphasis on patient welfare, health economics, and data accuracy as core value drivers.

Product portfolio and innovation

• Portfolio includes SippiⓇ (automated urine output measurement), UnoMeter™ family (including Safeti™ Plus and Abdo-Pressure™), and Biim (pocketable ultrasound).

• SippiⓇ automates urine monitoring, reduces infection risk, improves data accuracy, and saves staff time.

• UnoMeter™ Safeti™ Max, with patented infection control, is set for pilot study and expected launch in Q3/Q4 2025.

• All products are CE certified and supported by clinical documentation and marketing collateral.

Market opportunity and commercial strategy

• Global market for urine output measurement systems estimated at NOK 4 billion, with significant growth driven by ICU expansion and increased patient admissions.

• Market penetration strategy includes product evaluations, distributor activation, and public tender conversions, with 60-80% of market potential managed through tenders.

• Orders and repeat business secured across Europe and Asia, with ongoing expansion into new geographies.

• 85% geographical coverage achieved, with focus on growing share in established markets and selective expansion into Middle East, South America, and Australia/NZ.